Table of Contents Chapter 1 Overview of Metabolic Disorders Therapeutics 1.1 Definition of Metabolic Disorders Therapeutics in This Report 1.2 Commercial Types of Metabolic Disorders Therapeutics 1.2.1 Metachromatic Leukodystrophy 1.2.2 Globoid Leukodystrophy 1.2.3 Hepatic Encephalopathy 1.2.4 Others 1.3 Downstream Application of Metabolic Disorders Therapeutics 1.3.1 Diabetes 1.3.2 Obesity 1.3.3 Hypercholesterolemia 1.3.4 Lysosomal storage diseases 1.4 Development History of Metabolic Disorders Therapeutics 1.5 Market Status and Trend of Metabolic Disorders Therapeutics 2013-2023 1.5.1 North America Metabolic Disorders Therapeutics Market Status and Trend 2013-2023 1.5.2 Regional Metabolic Disorders Therapeutics Market Status and Trend 2013-2023 Chapter 2 North America Market Status and Forecast by Regions 2.1 Market Status of Metabolic Disorders Therapeutics in North America 2013-2017 2.2 Consumption Market of Metabolic Disorders Therapeutics in North America by Regions 2.2.1 Consumption Volume of Metabolic Disorders Therapeutics in North America by Regions 2.2.2 Revenue of Metabolic Disorders Therapeutics in North America by Regions 2.3 Market Analysis of Metabolic Disorders Therapeutics in North America by Regions 2.3.1 Market Analysis of Metabolic Disorders Therapeutics in United States 2013-2017 2.3.2 Market Analysis of Metabolic Disorders Therapeutics in Canada 2013-2017 2.3.3 Market Analysis of Metabolic Disorders Therapeutics in Mexico 2013-2017 2.4 Market Development Forecast of Metabolic Disorders Therapeutics in North America 2018-2023 2.4.1 Market Development Forecast of Metabolic Disorders Therapeutics in North America 2018-2023 2.4.2 Market Development Forecast of Metabolic Disorders Therapeutics by Regions 2018-2023 Chapter 3 North America Market Status and Forecast by Types 3.1 Whole North America Market Status by Types 3.1.1 Consumption Volume of Metabolic Disorders Therapeutics in North America by Types 3.1.2 Revenue of Metabolic Disorders Therapeutics in North America by Types 3.2 North America Market Status by Types in Major Countries 3.2.1 Market Status by Types in United States 3.2.2 Market Status by Types in Canada 3.2.3 Market Status by Types in Mexico 3.3 Market Forecast of Metabolic Disorders Therapeutics in North America by Types Chapter 4 North America Market Status and Forecast by Downstream Industry 4.1 Demand Volume of Metabolic Disorders Therapeutics in North America by Downstream Industry 4.2 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Major Countries 4.2.1 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in United States 4.2.2 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Canada 4.2.3 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Mexico 4.3 Market Forecast of Metabolic Disorders Therapeutics in North America by Downstream Industry Chapter 5 Market Driving Factor Analysis of Metabolic Disorders Therapeutics 5.1 North America Economy Situation and Trend Overview 5.2 Metabolic Disorders Therapeutics Downstream Industry Situation and Trend Overview Chapter 6 Metabolic Disorders Therapeutics Market Competition Status by Major Players in North America 6.1 Sales Volume of Metabolic Disorders Therapeutics in North America by Major Players 6.2 Revenue of Metabolic Disorders Therapeutics in North America by Major Players 6.3 Basic Information of Metabolic Disorders Therapeutics by Major Players 6.3.1 Headquarters Location and Established Time of Metabolic Disorders Therapeutics Major Players 6.3.2 Employees and Revenue Level of Metabolic Disorders Therapeutics Major Players 6.4 Market Competition News and Trend 6.4.1 Merger, Consolidation or Acquisition News 6.4.2 Investment or Disinvestment News 6.4.3 New Product Development and Launch Chapter 7 Metabolic Disorders Therapeutics Major Manufacturers Introduction and Market Data 7.1 Novo Nordisk 7.1.1 Company profile 7.1.2 Representative Metabolic Disorders Therapeutics Product 7.1.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Novo Nordisk 7.2 Sanofi 7.2.1 Company profile 7.2.2 Representative Metabolic Disorders Therapeutics Product 7.2.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Sanofi 7.3 Merck 7.3.1 Company profile 7.3.2 Representative Metabolic Disorders Therapeutics Product 7.3.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Merck 7.4 AstraZeneca 7.4.1 Company profile 7.4.2 Representative Metabolic Disorders Therapeutics Product 7.4.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca 7.5 Eli Lily 7.5.1 Company profile 7.5.2 Representative Metabolic Disorders Therapeutics Product 7.5.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lily 7.6 AbbVie 7.6.1 Company profile 7.6.2 Representative Metabolic Disorders Therapeutics Product 7.6.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie 7.7 Actelion Pharmaceuticals 7.7.1 Company profile 7.7.2 Representative Metabolic Disorders Therapeutics Product 7.7.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals 7.8 Adocia 7.8.1 Company profile 7.8.2 Representative Metabolic Disorders Therapeutics Product 7.8.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Adocia 7.9 Aegerion Pharmaceuticals 7.9.1 Company profile 7.9.2 Representative Metabolic Disorders Therapeutics Product 7.9.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Aegerion Pharmaceuticals 7.10 Akros Pharma 7.10.1 Company profile 7.10.2 Representative Metabolic Disorders Therapeutics Product 7.10.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Akros Pharma 7.11 Alnylam Pharmaceuticals 7.11.1 Company profile 7.11.2 Representative Metabolic Disorders Therapeutics Product 7.11.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals 7.12 Amarin 7.12.1 Company profile 7.12.2 Representative Metabolic Disorders Therapeutics Product 7.12.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amarin 7.13 Amicus Therapeutics 7.13.1 Company profile 7.13.2 Representative Metabolic Disorders Therapeutics Product 7.13.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amicus Therapeutics 7.14 Biopharma 7.14.1 Company profile 7.14.2 Representative Metabolic Disorders Therapeutics Product 7.14.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Biopharma 7.15 Arena Pharmaceuticals 7.15.1 Company profile 7.15.2 Representative Metabolic Disorders Therapeutics Product 7.15.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals 7.16 Astellas Pharma 7.17 Bionaturis 7.18 Diasome Pharmaceuticals 7.19 Lexicon Pharmaceuticals 7.20 Ligand Pharmaceuticals Chapter 8 Upstream and Downstream Market Analysis of Metabolic Disorders Therapeutics 8.1 Industry Chain of Metabolic Disorders Therapeutics 8.2 Upstream Market and Representative Companies Analysis 8.3 Downstream Market and Representative Companies Analysis Chapter 9 Cost and Gross Margin Analysis of Metabolic Disorders Therapeutics 9.1 Cost Structure Analysis of Metabolic Disorders Therapeutics 9.2 Raw Materials Cost Analysis of Metabolic Disorders Therapeutics 9.3 Labor Cost Analysis of Metabolic Disorders Therapeutics 9.4 Manufacturing Expenses Analysis of Metabolic Disorders Therapeutics Chapter 10 Marketing Status Analysis of Metabolic Disorders Therapeutics 10.1 Marketing Channel 10.1.1 Direct Marketing 10.1.2 Indirect Marketing 10.1.3 Marketing Channel Development Trend 10.2 Market Positioning 10.2.1 Pricing Strategy 10.2.2 Brand Strategy 10.2.3 Target Client 10.3 Distributors/Traders List Chapter 11 Report Conclusion Chapter 12 Research Methodology and Reference 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Reference

List of Tables Table Advantage and Disadvantage of Metachromatic Leukodystrophy Table Advantage and Disadvantage of Globoid Leukodystrophy Table Advantage and Disadvantage of Hepatic Encephalopathy Table Advantage and Disadvantage of Others Table Consumption Volume of Metabolic Disorders Therapeutics in North America by Regions 2013-2017 Table Revenue of Metabolic Disorders Therapeutics in North America by Regions 2013-2017 Table Consumption Volume of Metabolic Disorders Therapeutics in North America by Regions 2018-2023 Table Revenue of Metabolic Disorders Therapeutics in North America by Regions 2018-2023 Table Consumption Volume of Metabolic Disorders Therapeutics in North America by Types 2013-2017 Table Revenue of Metabolic Disorders Therapeutics in North America by Types 2013-2017 Table Consumption Volume of Metabolic Disorders Therapeutics by Types in United States 2013-2017 Table Consumption Volume of Metabolic Disorders Therapeutics by Types in Canada 2013-2017 Table Consumption Volume of Metabolic Disorders Therapeutics by Types in Mexico 2013-2017 Table Consumption Volume Forecast of Metabolic Disorders Therapeutics in North America by Types 2018-2023 Table Revenue Forecast of Metabolic Disorders Therapeutics in North America by Types 2018-2023 Table Demand Volume of Metabolic Disorders Therapeutics in North America by Downstream Industry 2013-2017 Table Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in United States 2013-2017 Table Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Canada 2013-2017 Table Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Mexico 2013-2017 Table Demand Volume Forecast of Metabolic Disorders Therapeutics in North America by Downstream Industry 2018-2023 Table Sales Volume of Metabolic Disorders Therapeutics in North America by Major Players 2013-2017 Table Revenue of Metabolic Disorders Therapeutics in North America by Major Players 2013-2017 Table Headquarters Location and Established Time of Metabolic Disorders Therapeutics Major Players Table Employees and Revenue Level of Metabolic Disorders Therapeutics Major Players Table Representative Metabolic Disorders Therapeutics Product One of Novo Nordisk Table Representative Metabolic Disorders Therapeutics Product Two of Novo Nordisk Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Novo Nordisk 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Sanofi Table Representative Metabolic Disorders Therapeutics Product Two of Sanofi Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Sanofi 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Merck Table Representative Metabolic Disorders Therapeutics Product Two of Merck Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Merck 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of AstraZeneca Table Representative Metabolic Disorders Therapeutics Product Two of AstraZeneca Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Eli Lily Table Representative Metabolic Disorders Therapeutics Product Two of Eli Lily Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lily 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of AbbVie Table Representative Metabolic Disorders Therapeutics Product Two of AbbVie Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Actelion Pharmaceuticals Table Representative Metabolic Disorders Therapeutics Product Two of Actelion Pharmaceuticals Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Adocia Table Representative Metabolic Disorders Therapeutics Product Two of Adocia Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Adocia 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Aegerion Pharmaceuticals Table Representative Metabolic Disorders Therapeutics Product Two of Aegerion Pharmaceuticals Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Aegerion Pharmaceuticals 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Akros Pharma Table Representative Metabolic Disorders Therapeutics Product Two of Akros Pharma Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Akros Pharma 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Alnylam Pharmaceuticals Table Representative Metabolic Disorders Therapeutics Product Two of Alnylam Pharmaceuticals Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Amarin Table Representative Metabolic Disorders Therapeutics Product Two of Amarin Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amarin 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Amicus Therapeutics Table Representative Metabolic Disorders Therapeutics Product Two of Amicus Therapeutics Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amicus Therapeutics 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Biopharma Table Representative Metabolic Disorders Therapeutics Product Two of Biopharma Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Biopharma 2013-2017 Table Representative Metabolic Disorders Therapeutics Product One of Arena Pharmaceuticals Table Representative Metabolic Disorders Therapeutics Product Two of Arena Pharmaceuticals Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals 2013-2017